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Sudden death in a child with epilepsy
Potential cerebellar mechanisms?
Fulvio A. Scorza1, Vera C. Terra2, Ricardo M. Arida3, 
Américo C. Sakamoto2, Ronald M. Harper4
ABSTRACT
Epilepsy is the most common neurological disorder in humans. People with epilepsy 
are more likely to die prematurely than those without epilepsy, with the most common 
epilepsy-related category of death being sudden unexpected death in epilepsy (SUDEP). 
The central mechanisms underlying the fatal process remain unclear, but cardiac and 
respiratory mechanisms appear to be involved. Recently, cerebellar, thalamic, basal 
ganglia and limbic brain structures have been shown to be implicated in respiratory and 
cardiac rate regulation. We discuss here the potential mechanisms underlying the fatal 
process, with a description of cerebellar actions likely failing in that SUDEP process. 
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RESUMO
Epilepsia é uma das doenças neurológicas mais comuns em seres humanos. Pessoas com 
epilepsia têm maior chance de morrer prematuramente do que pessoas sem epilepsia, 
sendo a principal causa de óbito a morte súbita em epilepsia (SUDEP). Os mecanismos 
centrais envolvidos neste processo fatal não são claros, mas mecanismos cardíacos 
e respiratórios parecem estar envolvidos. Recentemente, regiões cerebrais como o 
cerebelo, núcleos talâmicos, gânglios basais e estruturas límbicas foram relacionadas 
com a variação das frequências cardíaca e respiratória. Aqui, discutiremos potenciais 
mecanismos envolvidos na SUDEP, com uma descrição do possível papel do cerebelo 
na sua ocorrência.
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Epilepsy and long term evolution
Epi lepsies  are  one of  the most  
common serious brain disorders, and af-
fects approximately 50 million people 
worldwide1. Almost 25% of people devel-
oping epilepsy evolve with medically in-
tractable epilepsy, with a major propor-
tion of patients in the paediatric group2-4. 
Unfortunately, approximately one in 1000 
patients with chronic epilepsy will die 
suddenly, unexpectedly, and without ex-
planation each year5; suden unexpected 
death in epilepsy (SUDEP) is considered 
the most important direct epilepsy-related 
cause of death6. A number of associated 
factors for SUDEP have been assessed, 
with these factors including: refractori-
ness of the epileptic condition, presence 
of generalized tonic-clonic seizures, an-
tiepileptic medication (polytherapy with 
antiepileptic drugs), duration of the sei-
zure disorder, early onset of epilepsy, and 
young age7,8.
Understanding the mechanisms un-
derlying SUDEP may lead to identification 
of previously-unrecognized risk factors 
that are more amenable to correction9. 
Although different mechanisms may play 
separate roles in different cases7, the two 
major domains of potential mechanisms 
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of SUDEP are autonomic, i.e., cardiovascular, and respi-
ratory9. Pulmonary abnormalities, such as increased lung 
weight, pulmonary congestion, or edema, consequences 
of unrestrained autonomic action, appear frequently in 
postmortem examinations of SUDEP victims9. Both cen-
tral and obstructive apnea can occur during or imme-
diately after a seizure10. Obstructive apnea will usually 
complicate a generalized tonic-clonic seizure, whereas 
central apnea may occur during both partial and gener-
alized seizures10,11. Central hypoventilation and apnoea 
accompany generalized status epilepticus, and may be 
an important mechanism in a sheep model of epileptic 
sudden death12. A cardiovascular collapse, either from 
arrhythmia from the extreme sympathetic activation 
during a seizure, or from hypotension induced by asys-
tole from profound vagal activation during seizure dis-
charge is also possible.
Brain regions and SUDEP
Disorders of the central nervous system (CNS) can 
alter cardiovascular function13, and localized brain le-
sions or dysfunction can modify functional cardiovas-
cular and respiratory alterations. Recognition of these 
interactions has led to significant advances in under-
standing the brain sites involved with cardiovascular and 
respiratory control in adult humans14, and many of these 
sites lie outside classical “respiratory” or “cardiovascular” 
areas. Several of the sites are limbic regions, which are 
especially susceptible to seizure discharge, and other 
sites lie in the cerebellum, a structure ordinarily not con-
sidered as mediating breathing control, but now is rec-
ognized as a significant respiratory and cardiovascular 
regulatory site14-20. Cerebellar cardiovascular regulatory 
areas can dampen, i.e., limit extreme changes in hypoten-
sion or hypertension to ensure survival. The cerebellum 
is also responsible for integration of rapid cardiac re-
sponse to respiratory oscillations18, and cerebellar deep 
nuclei sense CO2 and respond to prolonged apnea16-20. 
Cerebellar roles in compensating for extreme changes in 
blood pressure or breathing suggests that failure within 
that structure would enhance the potential for SUDEP.
Of interest, cerebellar abnormalities are quite 
common in patients with chronic epilepsy, especially 
when patients are submitted to high doses of antiepi-
leptic drugs, with these patients being at increased risk 
for SUDEP. Recently, we followed a 9-year-old boy with 
a history of an uneventful pregnancy, born from a breech 
delivery with Apgar scores of 5 (first minute) and 8 (fifth 
minute) and who developed with moderate neurodevel-
opment delay. Medically-intractable epileptic seizures 
started at the age of five months. His seizures consisted 
of daily infantile spasms, and were treated with valproic 
acid, vigabatrin and predinisone without response. From 
age 3 to 5 years, he used a ketogenic diet, and was sei-
zure-free. Six months after the ketogenic diet withdrawal 
(his parents decided not to continue with the regimen), 
tonic seizures relapsed, with a frequency of one to two 
weekly. Magnetic resonance imaging revealed diffuse 
cerebral and cerebellar atrophy. The electroencephalo-
gram consisted of mild brain disorganized activity and 
rare multifocal spikes. An investigation for metabolic in-
born errors was normal. The patient was using pheno-
barbital (150 mg per day), and died during a prolonged 
tonic seizure. The patient was in an otherwise good state 
of health, and post-mortem examination did not reveal 
any abnormalities. Considering this evidence, the cause 
of death was considered a SUDEP.
In this patient with poorly controlled epilepsy who 
died suddenly during a tonic-clonic seizure, loss of re-
spiratory or cardiovascular regulation may be implicated, 
and may be induced by cerebellar abnormalities unable 
to perform normal regulatory functions. Several poten-
tial processes may have occurred; extreme hypotension 
or arrhythmia, sustained apneusis, or prolonged apnea, 
all outcomes in which protective cerebellar compensa-
tory action could have been beneficial if cerebellar struc-
tures were not damaged. The precise mechanisms under-
lying the processes are unclear; however, several pieces 
of evidence suggest the relationship we propose and the 
rationale for active pursuit. 
A major proportion of patients with epilepsy are pe-
diatric cases (18 years old or less), and approximately 
25% of those patients have medically intractable epi-
lepsy21. Only 10-20% of the children with epilepsy who 
continue to present with active epilepsy in adulthood 
will have spontaneous seizure remission, suggesting that 
early attempts to control the epilepsy should be pur-
sued22-24. Epilepsies in the pediatric group may be fre-
quently associated with known potentially risk factors 
for SUDEP. SUDEP remains a controversial and enig-
matic syndrome, particularly in children where the in-
cidence, prevalence and risk factors may differ from 
adults25. Contrary to the widespread opinion that SUDEP 
does not occur in children, the age of reported cases has 
ranged from 8 months to 83 years26. The incidence of 
SUDEP in children and adolescents is highly variable, but 
it is thought to be extremely rare in community-based 
studies27-29. Nevertheless, SUDEP has been identified as 
being the cause of mortality in 12% of the children fol-
lowed over a five-year period time, suggesting that the 
incidence may not be so rare30.
The respiratory changes accompanying increased 
seizure frequency also suggest SUDEP in this case. This 
child presented with high seizure frequency (one to two 
weekly) before death. Most studies that include infor-
mation on seizure control report a moderate or high 
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seizure frequency among SUDEP cases26, and SUDEP 
is considered rare in patients in remission, with only a 
few such cases reported26. Although few data exist about 
the risk of SUDEP in children, a recent study by our re-
search group demonstrated that increased SUDEP oc-
currence appeared in children unresponsive to anti-
epileptic therapy, with no increase in risk observed in 
patients who remained seizure free31.
An additional important issue is evidence that phe-
nytoin can exert toxic effects on the cerebellum in pa-
tients with epilepsy32; the toxicity is associated with 
ataxia, tremor, nystagmus and diplopia32,33. Furthermore, 
cerebellar atrophy can occur in phenytoin-exposed pa-
tients with epilepsy in the absence of generalised tonic-
clonic seizures or pre-existent brain damage32,34,35. Since 
the child evaluated in our study did not use phenytoin 
in his antiepileptic drug therapy schedule, our research 
group did not consider this issue.
Cerebellar and autonomic process
The principal evidence for cerebellar involvement 
was diffuse cerebellar atrophy revealed by magnetic 
resonance imaging. The evidence for a cerebellar role 
in breathing is substantial. Chokroverty and colleagues 
demonstrated a high incidence of obstructive sleep apnea 
in adults accompanying olivopontocerebellar degenera-
tion36. Massive intracerebellar hemorrhage (destruction 
of at least one-third of cerebellar tissue) is frequently ac-
companied by sudden death during sleep in low-birth-
weight infants37. Cerebellar damage, delayed develop-
ment38, or injury to a principal afferent structure, the 
olivary nucleus39 are all pathological findings reported 
in the sudden infant death syndrome (SIDS), a sleep-
related syndrome suspected of resulting from a failure 
of enhanced respiratory efforts to compensate for tran-
sient hypotension or an inability to recover from an ex-
cessive CO2 challenge14,40,41. Similar cerebellar injury was 
reported in patients with congenital central hypoventi-
lation syndrome, a condition with deficient response 
to hypercapnia and hypoxia, with possible dysfunction 
of cerebellar, thalamic, basal ganglia and limbic struc-
tures18,41. The deep cerebellar nuclei respond to chemo-
sensitive stimuli in both animal16,17 and human models18. 
Moreover, the fastigial deep cerebellar nuclei in the cer-
ebellum, when damaged, lead to death following hypo-
tension in animals19. The cerebellum, of course, does not 
act in isolation from its brainstem and other projections 
in these disrupted actions; compensatory action to re-
cover from extreme hypotension is mediated through 
cerebellar, vestibular, reticular formation, and ventral 
medullar blood pressure regulatory nuclei41, and che-
moreceptor mediation is mediated through medullary 
afferent and solitary tract nuclei, as well as through re-
spiratory motor structures17. From this evidence, we sug-
gest that a relationship exists between cerebellar abnor-
malities and SUDEP.
Cerebellar atrophy is a common finding in people 
suffering from epilepsy, including temporal lobe epi-
lepsy42-44, the most common form of partial epilepsy45 
and the commonest form of drug-refractory epilepsy42. 
Although the precise mechanisms are still debated, cer-
ebellar volume reduction in people with epilepsy is often 
attributed to age, presence of generalized tonic-clonic 
seizures, duration of epilepsy, antiepileptic medication, 
or the seizure activity itself42-44,46,47. Specht and colleagues 
demonstrated in 1997 that cerebellar atrophy diagnosed 
by MRI was a frequent finding in surgically treated pa-
tients with temporal lobe epilepsy44, and concluded that 
increased age, presence of generalized seizures, and in-
tellectual disability were the principal factors associated 
with cerebellar volume losses in their patients44. Botez 
and co-workers studied 134 adult patients with epilepsy 
using high-resolution CT scans, and found a higher in-
cidence of cerebellar atrophy with longer duration of ep-
ilepsy and treatment with phenytoin48. Convincing evi-
dence exists that prolonged phenytoin use, or a single 
episode of phenytoin intoxication can elicit severe and 
irreversible cerebellar atrophy42,44,49,50. Although chronic 
cerebellar stimulation suggests an inhibitory role for the 
cerebellum as an intervention for intractable seizures, 
cerebellar volume reduction may reduce these effects in 
patients with chronic epilepsy42,44,51. Furthermore, cere-
bellar atrophy, i.e., reductions in hemispheric Purkinje 
cell density, occurs in epilepsy patients52, a finding con-
firmed by the prominent expression of c-Jun staining of 
cerebellar Purkinje cells in some SUDEP cases53.
The mechanisms underlying cerebellar volume reduc-
tion in people with epilepsy may be similar to the pro-
cesses that result in risk factors for SUDEP. Cerebellar at-
rophy may lead to an inability to recover from apnea or 
apneusis, or failure to recover from extreme hypotension 
or arrhythmia, ultimately resulting in SUDEP in individ-
uals with refractory epilepsy. There are few studies that 
examine neuropathology with SUDEP; some studies sug-
gest amygdala central nucleus damage may contribute to 
SUDEP, especially since that structure can play a role in 
respiratory timing7-11.
Despite some progress, SUDEP remains a signifi-
cant clinical problem. Unfortunately, all the risk factors, 
mechanisms, and specific methods to prevent SUDEP 
are yet to be found54. Structural, functional and genetic 
factors are probable involved, and specific brain regions 
may be directly related. Considering these factors, de-
termination of which brain regions are mainly involved 
in SUDEP is essential to the understanding of SUDEP 
mechanisms and prevention. The study of cerebellar 
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functioning in patients with epilepsy may be of partic-
ularly interest.
The American Epilepsy Society and the Epilepsy 
Foundation Joint Task Force convened a task force to 
assess the state of knowledge (research directions, so-
cial, cultural and educational efforts) on SUDEP55. The 
potential functional significance of the cerebellum in re-
spiratory and cardiovascular dysfunction in people with 
chronic epilepsy is that the structure is a brain area with 
roles for respiratory and cardiovascular regulation, dys-
function of which can compromise life, and these issues 
represent a specific line of research in the SUDEP field 
that should be investigated. 
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